inobrodib

News

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

News

Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.